A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
The key catalyst for Cogent Biosciences (COGT) is the FDA's acceptance of its New Drug Application for bezuclastinib in NonAdvanced Systemic Mastocytosis, with a PDUFA target action date set for December 30, 2026. See our latest analysis for Cogent Biosciences. The share price recently closed at $35.41, with a 6.08% 1 day share price return following the FDA's NDA acceptance and mixed institutional trading. The 1 year total shareholder return of very large magnitude indicates strong longer term momentum despite weaker 90 day share price performance. If this kind of biotech catalyst has your attention, it might be a good moment to see what else is setting up in healthcare, including 36 healthcare AI stocks The stock has delivered substantial gains over the past year while still trading below the average analyst price target. This raises a key question for investors: does a buying opportunity remain, or is the market already pricing in future growth? Preferred Multiple of 10.
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch [Yahoo! Finance]Yahoo! Finance
- High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding [Yahoo! Finance]Yahoo! Finance
- Fidelity Small Cap Growth Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Cogent Biosciences (COGT) had its "outperform" rating reaffirmed by Wedbush. They now have a $55.00 price target on the stock.MarketBeat
- Cogent Biosciences (COGT) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
COGT
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form S-8
- 2/17/26 - Form SCHEDULE
- COGT's page on the SEC website